Irinotecan Hydrochloride Liposome

Drug Overview

Irinotecan Hydrochloride Liposome is a sophisticated, encapsulated formulation of the cytotoxic chemotherapy agent irinotecan. By housing the active drug within microscopic lipid spheres (liposomes), this formulation is designed to improve the drug’s stability, extend its circulation time in the blood, and enhance its accumulation within tumor tissues compared to standard irinotecan. Marketed under the brand name Onivyde®, it is a critical component in the management of advanced pancreatic cancer.

• Generic Name: Irinotecan Hydrochloride Liposome (or Liposomal Irinotecan)
• US Brand Name: Onivyde®
• Drug Class: Topoisomerase I Inhibitor (Liposomal formulation)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Approved (First approved in 2015; indication expanded in 2024)
  
  Irinotecan-hydrochloride-liposome offers the best hope for pancreatic cancer. See how this advanced formula delivers better results.

What Is It and How Does It Work? (Mechanism of Action)

Irinotecan hydrochloride liposome is a prodrug delivered via a nanotechnology-based carrier system.

Molecular Mechanism:

1. Liposomal Encapsulation: The active ingredient, irinotecan, is encapsulated in a lipid bilayer vesicle. This protects the drug from premature metabolism and clearance by the kidneys, significantly increasing its half-life in the bloodstream compared to free (non-liposomal) irinotecan.
2. Enhanced Permeability and Retention (EPR): Tumors often have leaky blood vessels and poor lymphatic drainage. The liposomes are small enough to pass through these leaky vessels and accumulate specifically in the tumor tissue, a phenomenon known as the EPR effect.
3. Bioactivation: Once inside the tumor microenvironment, macrophages engulf the liposomes, releasing the irinotecan.
4. Conversion to SN-38: The released irinotecan is metabolized by carboxylesterase enzymes into its active metabolite, SN-38. SN-38 is approximately 1,000 times more potent than irinotecan itself.
5. Topoisomerase I Inhibition: SN-38 binds to Topoisomerase I, a nuclear enzyme essential for DNA replication. It stabilizes the complex between the enzyme and DNA, preventing the re-ligation of DNA strands. This causes double-strand DNA breaks when the cell attempts to divide, leading to cell cycle arrest and apoptosis (cell death).

FDA Approved Clinical Indications

Irinotecan hydrochloride liposome is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma.

Oncological Uses:

• First-Line Treatment: In combination with oxaliplatin, fluorouracil, and leucovorin (regimen known as NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma.
• Second-Line Treatment: In combination with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.

Non-oncological Uses:

• There are currently no FDA-approved non-oncological indications.

Dosage and Administration Protocols

IMPORTANT: Onivyde® (liposomal irinotecan) is NOT interchangeable with Camptosar® (non-liposomal irinotecan). The dosing guidelines differ significantly.

Standard Dosing Regimens

• 
  Note: Doses are expressed as irinotecan free base. 70 mg/m² free base is equivalent to 80 mg/m² of irinotecan hydrochloride trihydrate salt.

Dose Adjustments:

• Homozygous UGT1A128 Allele (Gilbert’s Syndrome): Patients who are homozygous for the UGT1A128 allele metabolize the drug slower and are at higher risk for neutropenia.
  • 2nd Line: Reduce starting dose to 50 mg/m².
  • NALIRIFOX: Reduce starting dose to 50 mg/m² (no reduction needed as the standard dose is already 50 mg/m², but close monitoring is required; some protocols suggest starting lower depending on clinical judgment).
• Hepatic Impairment: No specific adjustment for mild impairment. Not recommended for use in patients with moderate or severe hepatic impairment (Total Bilirubin > 1.5 × ULN).
• Renal Impairment: No adjustment for mild to moderate impairment. Not studied in severe renal failure.

Clinical Efficacy and Research Results

Recent pivotal trials have established liposomal irinotecan as a new standard of care in pancreatic cancer.

• NAPOLI-3 Trial (2023/2024 Data):
  • Study Design: A Phase 3 trial comparing the NALIRIFOX regimen (Liposomal irinotecan + 5-FU/LV + Oxaliplatin) against the former standard, Gemcitabine + Nab-paclitaxel, in treatment-naïve metastatic pancreatic cancer.
  • Overall Survival (OS): NALIRIFOX demonstrated a statistically significant improvement in median OS (11.1 months vs. 9.2 months).
  • Progression-Free Survival (PFS): Median PFS was also superior in the NALIRIFOX arm (7.4 months vs. 5.6 months).
  • Impact: These results led to the FDA approval of NALIRIFOX as a first-line treatment in 2024, shifting the treatment paradigm.
• NAPOLI-1 Trial (Long-term Data):
  • In the second-line setting, the combination of liposomal irinotecan with 5-FU/LV showed a median OS of 6.1 months compared to 4.2 months for 5-FU/LV alone, confirming its utility in patients who have failed gemcitabine.

Safety Profile and Side Effects

BLACK BOX WARNINGS

1. Severe Neutropenia: Fatal neutropenic sepsis can occur. Withhold Onivyde for absolute neutrophil count below 1,500/mm³.
2. Severe Diarrhea: Severe and life-threatening diarrhea can occur. Do not administer to patients with bowel obstruction.

Common Side Effects (>20%)

• Gastrointestinal: Diarrhea (early and late onset), nausea, vomiting, decreased appetite, stomatitis.
• Constitutional: Fatigue, pyrexia (fever), weight loss.
• Hematologic: Neutropenia, anemia.
• Electrolytes: Hypokalemia (low potassium), hypomagnesemia.

Serious Adverse Events

• Late Diarrhea: Occurring more than 24 hours after infusion, this can lead to severe dehydration and electrolyte imbalance.
• Neutropenic Sepsis: Infection complications due to low white blood cell counts.
• Interstitial Lung Disease (ILD): Rare but potentially fatal inflammation of the lungs.
• Hypersensitivity Reactions: Severe allergic reactions during infusion.

Management Strategies:

• For Late Diarrhea: Patients MUST have loperamide (Imodium) at home. Start taking loperamide at the first sign of loose stools. Drink fluids with electrolytes.
• For Early Diarrhea (Cholinergic): Administer atropine (subcutaneous) if the patient experiences flushing, sweating, and abdominal cramping during the infusion.
• For Neutropenia: Dose interruptions or Granulocyte-Colony Stimulating Factors (G-CSF) may be required.

Research Areas: Nanotechnology

While irinotecan liposome is not a stem cell therapy, it is a prime example of Nanomedicine.

• Drug Delivery Systems: Research continues into using this liposomal platform to deliver other cytotoxic agents or to target specific tumor antigens by modifying the liposome surface (e.g., attaching antibodies to create immunoliposomes).
• Combination with Immunotherapy: Ongoing trials (2024-2025) are investigating the combination of liposomal irinotecan with PD-1 inhibitors (like nivolumab or pembrolizumab) to see if the chemotherapy can induce immunogenic cell death, making pancreatic tumors more responsive to immune attack.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• UGT1A1 Genotyping: Recommended to identify patients with Gilbert’s Syndrome who are at higher risk for toxicity.
• Complete Blood Count (CBC): To establish baseline neutrophil counts.
• Liver Function Tests: To ensure safe metabolism of the drug.

Precautions During Treatment:

• Diarrhea Kit: Ensure the patient has a supply of loperamide before the first infusion.
• Temperature Monitoring: Any fever > 100.4°F (38°C) requires immediate emergency evaluation due to the risk of neutropenia.

Do’s and Don’ts:

• DO take loperamide immediately if late diarrhea starts (loose stools >24 hours after treatment).
• DO stay hydrated. Pancreatic cancer patients are prone to dehydration.
• DON’T confuse this drug with standard irinotecan. The dosing is very different.
• DON’T take laxatives unless specifically instructed by your oncology team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is intended for international patients and healthcare professionals. It does not constitute medical advice, diagnosis, or treatment. Irinotecan Hydrochloride Liposome (Onivyde®) is a prescription medication; its use must be determined by a qualified oncologist based on individual patient history and genetic profiling. Dosing, protocols, and approval status may vary by country and regulatory jurisdiction. Always consult with a healthcare provider regarding specific medical conditions and treatment options.